1. Home
  2. RIGL

RIGL

Rigel Pharmaceuticals Inc.

Logo Rigel Pharmaceuticals Inc.

Health Care

Biotechnology: Pharmaceutical Preparations

Nasdaq

as 04-16-2024 4:00pm EST

$
-
.
-
-
-
$
-
.
-
-
-
-
.
-
-
%

Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's lead drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, the only oral spleen tyrosine kinase (SYK) inhibitor, Fostamatinib, R289, R552, R835, DS-3032, THF-beta Inhibitors, and AZD0449- Inhaled JAK Inhibitor.

Founded: N/A Country:
United States
United States
Employees: N/A City: SOUTH SAN FRANCISCO
Market Cap: 226.2M IPO Year: 2000
Target Price: $5.81 AVG Volume (30 days): 1.3M
Analyst Decision: Buy Number of Analysts: 4
Dividend Yield: N/A Dividend Payout Frequency: N/A
EPS: -0.14 EPS Growth: N/A
52 Week Low/High: $0.71 - $1.96 Next Earning Date: 04-30-2024
Revenue: $116,882,000 Revenue Growth: -2.79%
Revenue Growth (this year): 30.02% Revenue Growth (next year): 28.98%

Share on Social Networks: